Claims

[Claim 1]. Use of ~~A~~a compound ~~for use in~~in the manufacture of a medicament for the prevention of pre-eclampsia in a subject at risk of pre-eclampsia~~ or for use in the treatment of a subject suffering from pre-eclampsia~~, wherein said compound is a C1 esterase~~complement~~ inhibitor.

~~2. A compound for use according to claim 1, wherein the complement inhibitor is: an antibody, an agent inhibiting Factor XII activity, an agent inhibiting Kallikrein activity, an agent inhibiting bradykinin activity and/or an agent inhibiting C1 esterase activity.~~

~~3. A compound for use according to claim 1 or 2, wherein the complement inhibitor is a C1 esterase inhibitor.~~

[Claim 4~~2~~]. ~~A compound for~~The use according to claim 4~~1~~, wherein the C1 esterase inhibitor is an antibody.

[Claim 5~~3~~]. ~~A compound for~~The use according to claim 4~~2~~, wherein the C1 esterase inhibitor is a plasma-derived C1 esterase inhibitor.

[Claim 6~~4~~]. ~~A compound for~~The use according to claim 4~~2~~, wherein the C1 esterase inhibitor is a recombinant C1 esterase inhibitor, such as a C1 esterase inhibitor having an amino acid sequence that is ~~substantially~~ identical to the amino acid sequence of human plasma-derived C1 esterase inhibitor.

[Claim 7~~5~~]. ~~A compound for~~The use according to claim 4~~4~~, wherein the recombinant C1 esterase inhibitor is produced in a transgenic non-human mammal, such as a mouse, goat, bovine, sheep, porcine or an animal from the order *Lagomorpha*, such as a *Leporadae*, including a rabbit.

[Claim 8~~6~~]. ~~A compound for~~The use according to ~~any one of~~ claim~~s~~ 5~~-~~4 ~~-~~ or 7~~5~~, wherein the C1 esterase inhibitor has a modified carbohydrate structure ~~as compared to human plasma-derived C1 esterase inhibitor.~~

~~9. A compound for use according to claim 8, wherein the C1 esterase inhibitor has~~with a reduced level of terminal sialic acid residues as compared to plasma derived C1 esterase inhibitor, wherein said reduced level of terminal sialic acid residues ~~preferably~~ results in a plasma half-life of less than 6 hours.

[Claim ~~10~~7]. ~~A compound for~~The use according to any one of the preceding claims, wherein the compound is to be administered ~~to the subject~~ at least once a month, or at least once a week.

[Claim ~~11~~8]. ~~A compound for~~The use according to any one of claims ~~5~~ 3 – ~~10~~7, wherein the compound is ~~–~~to be administered in a dose ranging from 25 units/kg body weight to 100 units/kg body weight ~~per administration~~, or ranging from 50 units/kg body weight to 100 units/kg body weight ~~per administration~~.

[Claim ~~12~~9]. ~~A compound for~~The use according to any one of the preceding claims, wherein the subject is a pregnant mammal,

[Claim 10]. The use according to any one of the preceding claims, wherein the subject is~~preferably~~ a pregnant human.

[Claim ~~13~~11]. ~~A compound for~~The use according to any of the preceding claims, wherein the subject suffering from pre-eclampsia is suffering from early-onset pre-eclampsia (<34 weeks gestational age) or from late-onset pre-eclampsia (>34 weeks gestational age).

[Claim ~~14~~12]. ~~A compound for~~The use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.

[Claim ~~15~~13]. ~~A compound for~~The use according to any of the preceding claims, wherein the subject is diagnosed with pre-eclampsia or being at risk of pre-eclampsia by measurement of placenta-derived P-type inositolphosphoglycans (P-type IPG) in a bodily fluid, such as in blood or urine.

~~16. A compound for use according to claim 14 or 15, wherein the measurement is performed using the method as described in WO9810791.~~